CN107936091A - One kind targeting cell-penetrating peptide photosensitizer and its preparation method and application - Google Patents
One kind targeting cell-penetrating peptide photosensitizer and its preparation method and application Download PDFInfo
- Publication number
- CN107936091A CN107936091A CN201711119154.2A CN201711119154A CN107936091A CN 107936091 A CN107936091 A CN 107936091A CN 201711119154 A CN201711119154 A CN 201711119154A CN 107936091 A CN107936091 A CN 107936091A
- Authority
- CN
- China
- Prior art keywords
- cell
- photosensitizer
- penetrating peptide
- preparation
- tumor cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003504 photosensitizing agent Substances 0.000 title claims abstract description 72
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 title claims abstract description 41
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 title claims abstract description 41
- 230000008685 targeting Effects 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 206010041823 squamous cell carcinoma Diseases 0.000 claims abstract description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- -1 Selenium benzo phenoxazine class compound Chemical class 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 4
- 208000017520 skin disease Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 35
- 210000004881 tumor cell Anatomy 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 9
- 239000000126 substance Substances 0.000 abstract description 8
- 230000019491 signal transduction Effects 0.000 abstract description 6
- 230000004900 autophagic degradation Effects 0.000 abstract description 5
- 210000000170 cell membrane Anatomy 0.000 abstract description 5
- 231100000433 cytotoxic Toxicity 0.000 abstract description 4
- 230000001472 cytotoxic effect Effects 0.000 abstract description 4
- 230000034994 death Effects 0.000 abstract description 2
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 230000006907 apoptotic process Effects 0.000 description 23
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 12
- 102100021246 DDIT3 upstream open reading frame protein Human genes 0.000 description 11
- 102000003952 Caspase 3 Human genes 0.000 description 8
- 108090000397 Caspase 3 Proteins 0.000 description 8
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 8
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 8
- 101150112743 HSPA5 gene Proteins 0.000 description 8
- 101100111629 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR2 gene Proteins 0.000 description 8
- 108010057666 Transcription Factor CHOP Proteins 0.000 description 8
- 101150028578 grp78 gene Proteins 0.000 description 8
- 238000002428 photodynamic therapy Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 6
- 230000000149 penetrating effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 5
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 230000003698 anagen phase Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 229910052711 selenium Inorganic materials 0.000 description 5
- 239000011669 selenium Substances 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 4
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 3
- 108090000672 Annexin A5 Proteins 0.000 description 3
- 102000004121 Annexin A5 Human genes 0.000 description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- YOSZEPWSVKKQOV-UHFFFAOYSA-N 12h-benzo[a]phenoxazine Chemical compound C1=CC=CC2=C3NC4=CC=CC=C4OC3=CC=C21 YOSZEPWSVKKQOV-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 101710151717 Stress-related protein Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 101000911513 Homo sapiens Uncharacterized protein FAM215A Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
- 102100026728 Uncharacterized protein FAM215A Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- JVOGSHDZLOJKKR-MXFMKSRJSA-I [Na+].[Na+].[Na+].[Mg++].CCc1c(C)c2cc3[n-]c(c(C)c3C=C)c(C)c3nc(C[C@H]3CCC([O-])=O)c(CC([O-])=O)c3[n-]c(cc1n2)c(C)c3C([O-])=O Chemical class [Na+].[Na+].[Na+].[Mg++].CCc1c(C)c2cc3[n-]c(c(C)c3C=C)c(C)c3nc(C[C@H]3CCC([O-])=O)c(CC([O-])=O)c3[n-]c(cc1n2)c(C)c3C([O-])=O JVOGSHDZLOJKKR-MXFMKSRJSA-I 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000002186 photoactivation Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000005892 protein maturation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- 108020005087 unfolded proteins Proteins 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种靶向细胞穿膜肽光敏剂及其制备方法和应用,本发明涉及的靶向细胞穿膜肽光敏剂具有更高的靶向性,可以利用针对于鳞癌肿瘤细胞胞膜的靶向细胞穿膜肽和鳞癌肿瘤细胞胞膜上的转运蛋白相互作用,从而使光敏剂分子更好地进入和富集于鳞癌肿瘤细胞当中。本发明涉及的靶向细胞穿膜肽光敏剂可以激活鳞癌细胞内的PERK‑eIF信号通路诱导肿瘤细胞产生自噬,并且可以通过诱导自噬效应来促进鳞癌肿瘤细胞的死亡。本发明提升了肿瘤细胞对光敏剂的摩尔吸光率,更加充分地将光转换为细胞毒性物质,且本发明涉及的靶向细胞穿膜肽光敏剂更加符合肿瘤细胞的生物学特性,对鳞癌细胞靶向性更好。
The invention discloses a targeted cell-penetrating peptide photosensitizer and its preparation method and application. The targeted cell-penetrating peptide photosensitizer of the invention has higher targeting and can be used to target squamous cell carcinoma tumor cells. The membrane-targeting cell-penetrating peptide interacts with the transporter on the cell membrane of squamous cell carcinoma cells, so that the photosensitizer molecules can better enter and enrich in the squamous cell carcinoma tumor cells. The targeted cell-penetrating peptide photosensitizer of the present invention can activate the PERK-eIF signaling pathway in squamous cell carcinoma cells to induce tumor cells to produce autophagy, and can promote the death of squamous cell carcinoma tumor cells by inducing the autophagy effect. The present invention improves the molar absorptivity of tumor cells to photosensitizers, more fully converts light into cytotoxic substances, and the targeted cell-penetrating peptide photosensitizers of the present invention are more in line with the biological characteristics of tumor cells, and are effective for squamous cell carcinoma Cell targeting is better.
Description
技术领域technical field
本发明涉及一种靶向细胞穿膜肽光敏剂及其制备方法和应用。The invention relates to a targeted cell-penetrating peptide photosensitizer, a preparation method and application thereof.
背景技术Background technique
细胞穿膜肽是一类能携带不同生物活性物质透过细胞膜进入细胞内甚至细胞核当中而不损坏膜结构的一种短肽分子,其长度一般不超过30个氨基酸。细胞穿膜肽可以携带包括蛋白质、氨基酸、多肽、核酸和寡聚核苷酸等在内的多种物质进入细胞内,并且其穿膜能力不依赖经典的胞吞作用。目前,经过对天然细胞穿膜肽的化学结构和生物性质的研究,已经逐渐掌握了细胞穿膜肽的一些共有特性,比如:细胞穿膜肽富含精氨酸、赖氨酸等碱性氨基酸残基和其二级结构皆具有α-螺旋的空间构象。目前利用这些特性,已人工合成了穿透力更强、效率更高的人工穿膜肽,并且成功地携带药物大分子进入细胞发挥生物学活性。但是,目前还有对于将细胞穿膜肽同光敏剂分子相连接,来提高用于医学治疗的光敏剂的靶向性和治疗效果的报道。Cell-penetrating peptides are a type of short peptide molecules that can carry different biologically active substances through the cell membrane into the cell or even the nucleus without damaging the membrane structure, and its length generally does not exceed 30 amino acids. Cell-penetrating peptides can carry various substances including proteins, amino acids, polypeptides, nucleic acids, and oligonucleotides into cells, and their membrane-penetrating ability does not depend on classic endocytosis. At present, through the research on the chemical structure and biological properties of natural cell-penetrating peptides, some common characteristics of cell-penetrating peptides have been gradually grasped, such as: cell-penetrating peptides are rich in basic amino acids such as arginine and lysine Both residues and their secondary structures have an α-helical spatial conformation. At present, using these characteristics, artificial membrane-penetrating peptides with stronger penetrating power and higher efficiency have been artificially synthesized, and successfully carry drug macromolecules into cells to exert biological activity. However, there are still reports on linking cell-penetrating peptides with photosensitizer molecules to improve the targeting and therapeutic effect of photosensitizers used for medical treatment.
光动力疗法(Photodynamic Therapy,PDT)是近20年发展起来的一种可以应用于一种杀灭恶性肿瘤细胞的无创治疗方法。光敏剂是光动力治疗中的核心组成部分,光敏剂具有光化学活性,在一般状况下光敏剂本身安全无毒的,在特定的波长范围内,光敏剂分子吸收光子能量进行化学结构的转变或者产生化学效应,能够对肿瘤进行有效的抑制甚至杀灭。在光动力杀灭肿瘤细胞的过程中,可以通过对光照部位的严密控制,从而实现定向地消灭原发和复发肿瘤,很少损伤正常组织,毒副作用小。但是,到目前为止,开发的光敏剂尚存在不足之处,例如摩尔吸光率较低,不能充分地将光转换为细胞毒性物质;光敏剂不能有效地富集在特定的肿瘤细胞当中;光敏剂对于不同类型的肿瘤细胞的靶向性较差等。如中国发明,申请号:201210169784.1;授权公告号:CN 103193782B采用的光敏剂叶绿酸钠盐及其衍生物,均没有结合肿瘤的生物学特性进行修饰和改造,使其在肿瘤治疗的靶向性和有效性上存在提升的空间;再如论文(方倩.苯并吩恶嗪类(O、S、Se)水溶性光敏剂的合成与光学性能研究[D].中南大学,2012.)中研究的含硒原子苯并吩恶嗪类光敏剂虽然具有高效的光动力效应,但也只是由工业染料直接改造获得的高效光敏剂,没有能够针对不同的疾病和用途更好地适应生物学特点。Photodynamic therapy (Photodynamic Therapy, PDT) is a non-invasive treatment method developed in the past 20 years that can be applied to kill malignant tumor cells. Photosensitizer is the core component of photodynamic therapy. The photosensitizer has photochemical activity. Under normal circumstances, the photosensitizer itself is safe and non-toxic. In a specific wavelength range, the photosensitizer molecule absorbs photon energy to change the chemical structure or produce Chemical effects can effectively inhibit or even kill tumors. In the process of photodynamic killing of tumor cells, the targeted elimination of primary and recurrent tumors can be achieved through strict control of the light site, with little damage to normal tissues and less toxic and side effects. However, so far, the photosensitizers developed still have deficiencies, such as low molar absorptance, which cannot fully convert light into cytotoxic substances; photosensitizers cannot be effectively enriched in specific tumor cells; photosensitizers Poor targeting to different types of tumor cells, etc. Such as Chinese invention, application number: 201210169784.1; authorization announcement number: CN 103193782B The photosensitizer chlorophyllin sodium salt and its derivatives are not modified and transformed in combination with the biological characteristics of tumors, so that they can be used in the targeted treatment of tumors. There is room for improvement in terms of performance and effectiveness; another example is the paper (Fang Qian. Synthesis and optical properties of benzophenoxazine (O, S, Se) water-soluble photosensitizers [D]. Central South University, 2012.) Although the selenium-containing benzophenoxazine photosensitizers studied in the study have high-efficiency photodynamic effects, they are only high-efficiency photosensitizers obtained directly from industrial dyes, and they have not been able to better adapt to different diseases and uses in biology. features.
细胞凋亡是细胞是细胞死亡的主要机制之一,能被许多不同的信号诱导产生。很早以前就有人提出,肿瘤不仅是细胞增生异常引起的疾病,同时也是细胞死亡过低(应当死亡而未死亡)引起的。因此设法在肿瘤中诱导细胞凋亡成为一种新的治疗肿瘤的靶点。内质网是具有重要功能的细胞器,是真核细胞蛋白质合成,钙离子贮存以及脂肪质生成的主要场所。内质网的功能状态对蛋白质折叠、成熟及运转至关重要。细胞状态的改变可以干扰内质网的正常功能,使内质网功能紊乱,蛋白质出现错误折叠并与未折叠蛋白在腔内聚集,以及钙平衡紊乱都将引起内质网应激。PERK-eIF2α信号通路是内质网应激中的3条重要信号之一,活化PERK-eIF2α信号通路,能提高Bip(GRP78)和CHOP(GADD153)蛋白的表达,使细胞产生内质网应激,增加促凋亡和氧化蛋白的产物,诱导细胞凋亡。Apoptosis is one of the main mechanisms of cell death and can be induced by many different signals. It has long been proposed that tumors are not only diseases caused by abnormal cell proliferation, but also caused by low cell death (should be dead but not dead). Therefore trying to induce apoptosis in tumors has become a new target for the treatment of tumors. The endoplasmic reticulum is an organelle with important functions, and it is the main place for protein synthesis, calcium ion storage and lipogenesis in eukaryotic cells. The functional state of the endoplasmic reticulum is critical for protein folding, maturation, and movement. Changes in the cell state can interfere with the normal function of the ER, causing ER dysfunction, protein misfolding and aggregation in the lumen with unfolded proteins, and disturbances in calcium balance will all cause ER stress. The PERK-eIF2α signaling pathway is one of the three important signals in endoplasmic reticulum stress. Activating the PERK-eIF2α signaling pathway can increase the expression of Bip (GRP78) and CHOP (GADD153) proteins, causing cells to generate endoplasmic reticulum stress , increases the production of pro-apoptotic and oxidized proteins, and induces apoptosis.
利用PDT通过凋亡途径来治疗肿瘤有着许多优点,在有些癌症中,可以通过促进肿瘤细胞的凋亡达到治疗肿瘤的作用,在有些癌症中,可以通过抑制细胞凋亡达到治疗肿瘤的目,细胞凋亡也可以增强以细胞信号转导为靶点的抗肿瘤药物作用等。因此利用光敏剂如何控制光动力治疗过程中的凋亡,提高光动力的疗效是一个值得研究的课题。Using PDT to treat tumors through apoptosis has many advantages. In some cancers, it can achieve the effect of treating tumors by promoting the apoptosis of tumor cells. In some cancers, it can achieve the purpose of treating tumors by inhibiting apoptosis. Apoptosis can also enhance the effect of antitumor drugs targeting cell signal transduction, etc. Therefore, how to use photosensitizers to control apoptosis in the process of photodynamic therapy and improve the efficacy of photodynamic therapy is a subject worth studying.
发明内容Contents of the invention
本发明解决的技术问题是,提高光敏剂药物的靶向性,升高肿瘤细胞对光敏剂的摩尔吸光率,更加充分地将光转换为细胞毒性物质。The technical problem solved by the invention is to improve the targeting of photosensitizer drugs, increase the molar absorbance of tumor cells to photosensitizers, and more fully convert light into cytotoxic substances.
本发明的技术方案是,提供一种靶向细胞穿膜肽光敏剂,所述穿膜肽光敏剂的结构式为:The technical solution of the present invention is to provide a targeted cell-penetrating peptide photosensitizer, the structural formula of which is:
其中R基团为:羧基、羟基、甲基、乙基、乙酰基、苯基中的任意一种。Wherein the R group is any one of carboxyl, hydroxyl, methyl, ethyl, acetyl and phenyl.
本发明进一步提供上述穿膜肽光敏剂的制备方法,包括以下步骤:分别将含硒苯并吩恶嗪类化合物和穿膜肽溶解,按硒苯并吩恶嗪类化合物和穿膜肽的摩尔比为1:5-8进行反应,得到穿膜肽光敏剂,反应式如下:The present invention further provides a preparation method of the above membrane-penetrating peptide photosensitizer, comprising the following steps: respectively dissolving the selenium-containing benzophenoxazine compound and the membrane-penetrating peptide, and The ratio is 1:5-8 to react to obtain the penetrating peptide photosensitizer, and the reaction formula is as follows:
优选地,将含硒苯并吩恶嗪类化合物在45℃-52℃的条件下溶解于丙酮或乙醇溶液中。Preferably, the selenium-containing benzophenoxazine compound is dissolved in acetone or ethanol solution under the condition of 45°C-52°C.
优选地,将穿膜肽在pH为6.8-7.2的条件下溶解于DMSO溶液中。Preferably, the penetrating peptide is dissolved in DMSO solution at a pH of 6.8-7.2.
优选地,反应4-6小时后,使用截留分子量为8000-12000的透析袋去除未反应的小分子和杂质。Preferably, after 4-6 hours of reaction, a dialysis bag with a molecular weight cut-off of 8000-12000 is used to remove unreacted small molecules and impurities.
本发明还提供上述穿膜肽光敏剂在制备治疗皮肤疾病的药物中的应用。The present invention also provides the application of the above membrane-penetrating peptide photosensitizer in the preparation of medicines for treating skin diseases.
优选地,所述皮肤疾病为基底细胞癌、鳞状细胞癌、恶性黑素瘤、湿疹样癌和帕哲病。Preferably, the skin disease is basal cell carcinoma, squamous cell carcinoma, malignant melanoma, eczematoid carcinoma and Paget's disease.
靶向细胞穿膜肽光敏剂的激发光源可以为:超音波照射发生器、光发射电子管、激光电子管、燃料激光、卤族金属灯、闪光灯、机械滤过的荧光光源、日光或机械滤过的日光、或白热线光源中的一种或多种。光激发包括光敏剂的组合物时,对光强度没有限制,光强度减弱时适当的延长照射时间或增加照射次数;光强度强时,适当的减少照射时间或减少照射次数来调整光敏剂的光活化。光激发包括光敏剂的组合物时,最好适当的把控光强度,强度太弱或太强都会影响到光活化程度,光太强会引起正常皮肤组织的损伤等不良效果,光太弱无法渗透靶组织,对光敏剂不能起到光活化的作用。因此,激发光源的光波长范围是580~650nm,光强度的最佳范围是0.5~10J/cm2。除照射强度外,对照射时间也没有限制。要想达到效果好且对正常皮肤无损伤的条件,除了有最佳的照射光强度外,照射同样也有最佳照射时间,最佳照射时间为5min~15min,光照射次数为1次。The excitation light source targeting the cell-penetrating peptide photosensitizer can be: ultrasonic irradiation generator, light emitting electron tube, laser electron tube, fuel laser, halogen metal lamp, flash lamp, mechanically filtered fluorescent light source, daylight or mechanically filtered One or more of daylight or incandescent light sources. When light excites the composition including the photosensitizer, there is no limit to the light intensity. When the light intensity is weakened, the irradiation time or the number of times of irradiation should be appropriately extended; activation. When light excites the composition including the photosensitizer, it is best to properly control the light intensity. Too weak or too strong light will affect the degree of photoactivation. Too strong light will cause damage to normal skin tissue and other adverse effects. Too weak light cannot penetrate the target. Tissues cannot be photoactivated by photosensitizers. Therefore, the light wavelength range of the excitation light source is 580-650 nm, and the optimal range of light intensity is 0.5-10 J/cm 2 . In addition to the irradiation intensity, there is no limitation on the irradiation time. In order to achieve a good effect and no damage to normal skin, in addition to the optimal irradiation light intensity, there is also an optimal irradiation time. The optimal irradiation time is 5 minutes to 15 minutes, and the number of light irradiations is 1 time.
靶向细胞穿膜肽光敏剂中可以包含可接受的赋形剂或辅料。所述辅料或赋形剂包括但不限于甘露醇、亚硫酸氢钠、淀粉、糊精粉、无水乙醇、注射用水、糖粉、乳糖、羟丙甲纤维素、硬脂酸镁、蔗糖、聚维酮K30。靶向细胞穿膜肽光敏剂以液体、半固体、固体或者气雾剂形态使用。例如水溶性或者非溶性浑悬液、溶液、乳剂(包括膏霜)、软膏、凝胶、浆液、栓剂、片剂、胶囊或者细微喷雾剂等形态被使用。The photosensitizer targeting cell-penetrating peptides may contain acceptable excipients or auxiliary materials. The auxiliary materials or excipients include but are not limited to mannitol, sodium bisulfite, starch, dextrin powder, absolute ethanol, water for injection, powdered sugar, lactose, hypromellose, magnesium stearate, sucrose, Povidone K30. The targeted cell-penetrating peptide photosensitizer is used in the form of liquid, semi-solid, solid or aerosol. Forms such as water-soluble or insoluble suspensions, solutions, emulsions (including creams), ointments, gels, slurries, suppositories, tablets, capsules or fine sprays are used.
本发明的有益效果是:本发明涉及的靶向细胞穿膜肽光敏剂,提升了肿瘤细胞对光敏剂的摩尔吸光率,更加充分地将光转换为细胞毒性物质。同时具有更高的靶向性,本发明涉及的靶向细胞穿膜肽光敏剂更加切合肿瘤细胞的生物学特性,采用穿膜肽与癌细胞表面蛋白相互作用,使光敏剂分子更好地进入和富集于鳞癌肿瘤细胞当中,对鳞癌肿瘤细胞的靶向性更好。根据以A-431细胞进行的体外实验,本发明涉及的靶向细胞穿膜肽光敏剂可以通过激活鳞癌细胞内的PERK-eIF信号通路来诱导肿瘤细胞产生自噬,并且可以通过诱导自噬效应来促进鳞癌肿瘤细胞的死亡。The beneficial effects of the present invention are: the targeted cell-penetrating peptide photosensitizer of the present invention increases the molar absorbance of tumor cells to the photosensitizer, and more fully converts light into cytotoxic substances. At the same time, it has higher targeting. The targeted cell-penetrating peptide photosensitizer of the present invention is more in line with the biological characteristics of tumor cells. The membrane-penetrating peptide is used to interact with cancer cell surface proteins, so that the photosensitizer molecules can better enter and enriched in squamous cell carcinoma tumor cells, better targeting of squamous cell carcinoma tumor cells. According to the in vitro experiments conducted with A-431 cells, the targeted cell-penetrating peptide photosensitizer of the present invention can induce tumor cells to produce autophagy by activating the PERK-eIF signaling pathway in squamous cell carcinoma cells, and can induce autophagy by inducing autophagy effect to promote the death of squamous cell carcinoma tumor cells.
附图说明Description of drawings
图1表示靶向细胞穿膜肽光敏剂的化学结构式。Figure 1 shows the chemical structural formula of a photosensitizer targeting a cell-penetrating peptide.
图2表示靶向细胞穿膜肽光敏剂的氢谱。Figure 2 shows the hydrogen spectra of photosensitizers targeting cell-penetrating peptides.
图3表示靶向细胞穿膜肽光敏剂的碳谱。Figure 3 shows the carbon spectrum of a photosensitizer targeting a cell-penetrating peptide.
图4表示A431鳞癌细胞流式细胞图。Fig. 4 shows a flow cytogram of A431 squamous cell carcinoma cells.
图5表示凋亡相关蛋白Western Blot结果图。Figure 5 shows the results of Western Blot of apoptosis-related proteins.
图6表示内质网应激相关蛋白Western Blot结果图。Figure 6 shows the results of Western Blot of endoplasmic reticulum stress-related proteins.
图7表示凋亡和内质网应激相关蛋白免疫细胞荧光结果图。Figure 7 shows the results of immunocytofluorescence of apoptosis and endoplasmic reticulum stress-related proteins.
具体实施方式Detailed ways
下面结合实施例对本发明作进一步说明。The present invention will be further described below in conjunction with embodiment.
实施例1Example 1
穿膜肽光敏剂的制备方法:包括以下步骤:将含硒苯并吩恶嗪类化合物在45℃-52℃的条件下溶解于丙酮或乙醇溶液中;将穿膜肽在pH为6.8-7.2的条件下溶解于DMSO溶液中。按硒苯并吩恶嗪类化合物和穿膜肽的摩尔比为1:5-8进行反应,得到穿膜肽光敏剂,反应式如下:The preparation method of the membrane-penetrating peptide photosensitizer comprises the following steps: dissolving the selenium-containing benzophenoxazine compound in acetone or ethanol solution under the condition of 45°C-52°C; dissolved in DMSO solution under the conditions. The molar ratio of the selenium benzophenoxazine compound and the penetrating peptide is 1:5-8 to react to obtain the penetrating peptide photosensitizer, and the reaction formula is as follows:
将上述目标产物用氢谱(图2)和碳谱(图3)进行验证,可以确认本发明成功地合成了上述穿膜肽光敏剂。The above target product was verified by hydrogen spectrum (Figure 2) and carbon spectrum (Figure 3), which confirmed that the present invention successfully synthesized the above-mentioned penetrating peptide photosensitizer.
实施例2:靶向细胞穿膜肽光敏剂使皮肤肿瘤细胞产生凋亡实验Example 2: Targeting cell-penetrating peptide photosensitizer to induce apoptosis of skin tumor cells
Annexin V是一种检测细胞凋亡的试剂,在正常细胞中,磷脂酰丝氨酸只分布在细胞膜脂质双层的内侧,细胞发生凋亡早期,膜磷脂酰丝氨酸(PS)由脂膜内侧翻向外侧。因此Annexin V是检测细胞早期凋亡的灵敏指标。PI(碘化丙啶)是一种可对DNA染色的细胞核染色试剂,尽管PI不能通过活细胞膜,但却能穿过破损的细胞膜而对核染色。因此Annexin V和PI联合使用能同时对活细胞和死细胞染色。Annexin V is a reagent for detecting cell apoptosis. In normal cells, phosphatidylserine is only distributed on the inner side of the lipid bilayer of the cell membrane. In the early stage of cell apoptosis, the membrane phosphatidylserine (PS) is turned from the inner side of the lipid membrane to outside. Therefore, Annexin V is a sensitive indicator for detecting early cell apoptosis. PI (propidium iodide) is a nuclear staining reagent that can stain DNA. Although PI cannot pass through the living cell membrane, it can pass through the damaged cell membrane and stain the nucleus. Therefore, the combination of Annexin V and PI can stain live and dead cells at the same time.
(1)实验方法(1) Experimental method
鳞癌细胞A-431细胞系培养于10%小牛血清的DMEM培养液中,添加100IU/L的青霉素和100mg/L的链霉素,置于37℃,5%CO2的恒温培养箱中常规培养,待细胞长满瓶底后,弃掉培养液,PBS液冲洗两次,再用0.25%的胰酶和0.02%的EDTA消化5分钟,再分瓶培养,2至3天传代一次,取对数生长期细胞用于实验。The squamous cell carcinoma A-431 cell line was cultured in DMEM medium with 10% calf serum, added with 100IU/L penicillin and 100mg/L streptomycin, and placed in a constant temperature incubator at 37°C and 5% CO2. Cultivate, after the cells grow to the bottom of the bottle, discard the culture medium, wash twice with PBS solution, then digest with 0.25% trypsin and 0.02% EDTA for 5 minutes, then culture in separate bottles, passaging once every 2 to 3 days, and take Cells in logarithmic growth phase were used for experiments.
取对数生长期的A-431细胞经胰酶消化后接种于六孔培养板中,置于5%CO2培养箱,37℃培养,待生长至80%~90%融合状态时,分别加入400nM蒸馏水,400nM的一种靶向细胞穿膜肽光敏剂,400nM光敏剂+4-PBA(内质网应激抑制剂)和400nM光敏剂+Tunicamycin(内质网应激促进剂)孵育1h后,用20J/cm2的红光照射15min,16h后用Annexin V–PI染色,通过FACSCalibur flow cytometer观察细胞发生凋亡的情况。A-431 cells in the logarithmic growth phase were digested with trypsin and inoculated into six-well culture plates, placed in a 5% CO2 incubator, and cultured at 37°C. When they grew to 80% to 90% confluent, 400nM Distilled water, 400nM of a targeted cell-penetrating peptide photosensitizer, 400nM photosensitizer + 4-PBA (endoplasmic reticulum stress inhibitor) and 400nM photosensitizer + Tunicamycin (endoplasmic reticulum stress promoter) after incubation for 1h, Irradiated with 20J/cm 2 red light for 15min, stained with Annexin V-PI after 16h, and observed cell apoptosis by FACSCalibur flow cytometer.
(2)实验结果(2) Experimental results
流式检测结果显示,A-431细胞经过一种靶向细胞穿膜肽光敏剂的光动力反应后,后16h产生的细胞凋亡比空白组增加了35.5%(图4),一种靶向细胞穿膜肽光敏剂的光动力反应联合内质网应激抑制剂能轻微的减少细胞凋亡3%,然而一种靶向细胞穿膜肽光敏剂的光动力反应联合内质网应激促进剂能提高该光敏剂诱导的细胞凋亡43.4%。从结果分析,400nM一种靶向细胞穿膜肽光敏剂的光动力反应能明显诱导细胞产生凋亡,并且内质网应激促进剂联合该光敏剂进行光动力反应能明显提高其对A-431细胞诱导凋亡的能力。The results of flow cytometry showed that after the photodynamic reaction of A-431 cells with a photosensitizer targeting cell-penetrating peptides, the apoptosis rate of A-431 cells increased by 35.5% compared with the blank group after 16 hours (Figure 4). The photodynamic response of a cell-penetrating peptide photosensitizer combined with an ER stress inhibitor slightly reduced apoptosis by 3%, whereas a photodynamic response of a cell-penetrating peptide photosensitizer combined with ER stress promoted The photosensitizer can increase the apoptosis induced by the photosensitizer by 43.4%. From the analysis of the results, the photodynamic response of a photosensitizer targeting cell-penetrating peptide at 400nM can significantly induce cell apoptosis, and the photodynamic reaction of the endoplasmic reticulum stress promoter combined with the photosensitizer can significantly improve its response to A- The ability of 431 cells to induce apoptosis.
实施例2:靶向细胞穿膜肽光敏剂的光动力反应诱导细胞凋亡和内质网应激实验Example 2: Photodynamic response-induced apoptosis and endoplasmic reticulum stress experiments targeting cell-penetrating peptide photosensitizers
PERK-eIF2α信号通路是内质网应激中的三条重要信号之一,启动PERK-eIF2α信号,能明显促进细胞产生内质网应激,并且提高GADD153(CHOP)和GRP78(Bip)的表达量,说明内质网应激产生。Caspase-3和Bcl-2是细胞凋亡的重要指标,Caspase-3表达增加和Bcl-2表达量的抑制是细胞产生凋亡的重要标志。The PERK-eIF2α signaling pathway is one of the three important signals in the endoplasmic reticulum stress. Activating the PERK-eIF2α signal can significantly promote the generation of endoplasmic reticulum stress in cells and increase the expression of GADD153 (CHOP) and GRP78 (Bip) , indicating that endoplasmic reticulum stress occurs. Caspase-3 and Bcl-2 are important indicators of cell apoptosis, and the increase of Caspase-3 expression and the inhibition of Bcl-2 expression are important signs of cell apoptosis.
(1)实验方法(1) Experimental method
鳞癌细胞A-431细胞系培养于10%小牛血清的DMEM培养液中,添加100IU/L的青霉素和100mg/L的链霉素,置于37℃,5%CO2的恒温培养箱中常规培养,待细胞长满瓶底后,弃掉培养液,PBS液冲洗两次,再用0.25%的胰酶和0.02%的EDTA消化5分钟,再分瓶培养,2至3天传代一次,取对数生长期细胞用于实验。The squamous cell carcinoma A-431 cell line was cultured in DMEM medium with 10% calf serum, added with 100IU/L penicillin and 100mg/L streptomycin, and placed in a constant temperature incubator at 37°C and 5% CO2. Cultivate, after the cells grow to the bottom of the bottle, discard the culture medium, wash twice with PBS solution, then digest with 0.25% trypsin and 0.02% EDTA for 5 minutes, then culture in separate bottles, passaging once every 2 to 3 days, and take Cells in logarithmic growth phase were used for experiments.
取对数生长期的A-431细胞经胰酶消化后接种于六孔培养板中,置于5%CO2培养箱,37℃培养,待生长至80%~90%融合状态时,在每孔中分别加入本发明涉及的光敏剂,使其终浓度分别为0nM,100nM,200nM,400nM,800nM,孵育1h后,用20J/cm2的红光照射15min,分别于0.5h后和16h后收集细胞提取总蛋白用Western Blot法检测细胞中p-PERK、p-eIF2α、Caspase-3、Bcl-2、GADD153和GRP78。A-431 cells in the logarithmic growth phase were digested with trypsin and inoculated in a six-well culture plate, placed in a 5% CO2 incubator, and cultured at 37°C. Add the photosensitizers involved in the present invention to make the final concentration respectively 0nM, 100nM, 200nM, 400nM, 800nM, after incubation for 1h, irradiate with 20J/ cm2 red light for 15min, and collect after 0.5h and 16h respectively The total protein extracted from cells was detected by Western Blot method to detect p-PERK, p-eIF2α, Caspase-3, Bcl-2, GADD153 and GRP78 in cells.
取对数生长期的A-431细胞经胰酶消化后接种于六孔培养板中,置于5%CO2培养箱,37℃培养,待生长至80%~90%融合状态时,加入400nM本发明涉及的光敏剂孵育1h后,用20J/cm2的红光照射15min,16h后用收集细胞进行免疫荧光染色,观察细胞Caspase-3、GADD153和GRP78表达量变化。A-431 cells in the logarithmic growth phase were digested with trypsin and inoculated into six-well culture plates, placed in a 5% CO2 incubator, and cultured at 37°C. When they grew to 80% to 90% confluent, 400nM After the photosensitizer involved in the invention was incubated for 1 hour, it was irradiated with 20 J/cm 2 red light for 15 minutes, and after 16 hours, the cells were collected for immunofluorescence staining, and the expression changes of Caspase-3, GADD153 and GRP78 in the cells were observed.
(2)实验结果(2) Experimental results
梯度剂量本发明涉及的光敏剂就进行光动力处理A-431细胞对其p-PERK、p-eIF2α、Caspase-3、Bcl-2、GADD153和GRP78表达量Western Blot结果分析发现,p-PERK、p-eIF2α和GADD153表达量随着本发明涉及的光敏剂剂量增加表达量明显增高,而p-PERK在光敏剂浓度600nM时达到峰值(图5、图6)。Caspase-3和GRP78表达量在经过一种靶向细胞穿膜肽光敏剂的光动力反应处理后提升,在光敏剂200nM时达到峰值。细胞免疫荧光实验也明显的说明400nM的一种靶向细胞穿膜肽光敏剂的光动力反应能明显促进Caspase-3、GADD153(又名Bip)和GRP78(又名CHOP)表达量增加(图7)。p-PERK、p-eIF2α、GADD153和GRP78表达增加说明一种靶向细胞穿膜肽光敏剂的光动力反应能明显诱导A-431细胞产生内质网应激,而Caspase-3表达量增加和Bcl-2表达量的减少说明该种光敏剂能明显诱导A-431细胞凋亡。Gradient dosage of the photosensitizer involved in the present invention was carried out on photodynamically treated A-431 cells to analyze the Western Blot results of the expression levels of p-PERK, p-eIF2α, Caspase-3, Bcl-2, GADD153 and GRP78 and found that p-PERK, The expression levels of p-eIF2α and GADD153 increased significantly with the increase of the dosage of the photosensitizer involved in the present invention, while p-PERK reached the peak when the concentration of the photosensitizer was 600nM ( FIG. 5 , FIG. 6 ). The expression levels of Caspase-3 and GRP78 were increased after photodynamic treatment with a photosensitizer targeting cell-penetrating peptides, and reached a peak at 200 nM of the photosensitizer. Cell immunofluorescence experiments also clearly demonstrated that the photodynamic reaction of a 400nM targeted cell-penetrating peptide photosensitizer can significantly increase the expression of Caspase-3, GADD153 (also known as Bip) and GRP78 (also known as CHOP) (Figure 7 ). The increased expressions of p-PERK, p-eIF2α, GADD153 and GRP78 indicate that the photodynamic response of a photosensitizer targeting cell-penetrating peptides can significantly induce endoplasmic reticulum stress in A-431 cells, while the expression of Caspase-3 and The reduction of the expression of Bcl-2 indicated that the photosensitizer can obviously induce the apoptosis of A-431 cells.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711119154.2A CN107936091A (en) | 2017-11-13 | 2017-11-13 | One kind targeting cell-penetrating peptide photosensitizer and its preparation method and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711119154.2A CN107936091A (en) | 2017-11-13 | 2017-11-13 | One kind targeting cell-penetrating peptide photosensitizer and its preparation method and application |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107936091A true CN107936091A (en) | 2018-04-20 |
Family
ID=61935009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711119154.2A Pending CN107936091A (en) | 2017-11-13 | 2017-11-13 | One kind targeting cell-penetrating peptide photosensitizer and its preparation method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107936091A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109513004A (en) * | 2018-11-26 | 2019-03-26 | 中南大学湘雅三医院 | A kind of photosensitizer and preparation method thereof for photodynamic therapy |
WO2023092708A1 (en) * | 2021-11-25 | 2023-06-01 | 深圳先进技术研究院 | Cell-penetrating riboflavin complex and application thereof in preparation of photodynamic therapy drug |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1894003A (en) * | 2003-10-16 | 2007-01-10 | 光科学公司 | Photodynamic therapy for local adipocyte reduction |
US20080015189A1 (en) * | 2006-06-20 | 2008-01-17 | The General Hospital Corporation | Antimicrobial photoinactivation using chalcogen analogs of benzo(A)phenoxazinium dyes |
CN103193782A (en) * | 2012-05-28 | 2013-07-10 | 复旦大学附属金山医院 | Photosensitizer sodium chlorophyllin derivatives and their preparation method and use |
WO2014122228A1 (en) * | 2013-02-07 | 2014-08-14 | Westfaelische Wilhelms-Universitaet Muenster | Labelled compounds that bind to alpha-v-beta-3 integrin |
CN104940950A (en) * | 2015-07-09 | 2015-09-30 | 武汉大学 | Tumor targeted polypeptide photosensitizer bonding object |
-
2017
- 2017-11-13 CN CN201711119154.2A patent/CN107936091A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1894003A (en) * | 2003-10-16 | 2007-01-10 | 光科学公司 | Photodynamic therapy for local adipocyte reduction |
US20080015189A1 (en) * | 2006-06-20 | 2008-01-17 | The General Hospital Corporation | Antimicrobial photoinactivation using chalcogen analogs of benzo(A)phenoxazinium dyes |
CN103193782A (en) * | 2012-05-28 | 2013-07-10 | 复旦大学附属金山医院 | Photosensitizer sodium chlorophyllin derivatives and their preparation method and use |
WO2014122228A1 (en) * | 2013-02-07 | 2014-08-14 | Westfaelische Wilhelms-Universitaet Muenster | Labelled compounds that bind to alpha-v-beta-3 integrin |
CN104940950A (en) * | 2015-07-09 | 2015-09-30 | 武汉大学 | Tumor targeted polypeptide photosensitizer bonding object |
Non-Patent Citations (5)
Title |
---|
JAMES W. FOLEY 等: "Synthesis and Properties of Benzo[a]phenoxazinium Chalcogen Analogues as Novel Broad-Spectrum Antimicrobial Photosensitizers", 《J MED CHEM. 》 * |
JING CHEN 等: "endoplasmic reticulum stress-mediated autophagy contributes to 5-ethylamino-9-diethylaminobenzo[a]phenoselenaziniummed mediated photodynamic therapy via the PerK–eiF2α pathway", 《ONCOTARGETS AND THRAPY》 * |
VAˆ NIA H. J. FRADE 等: "Synthesis of fluorescent water-soluble functionalised benzo[ a]phenoxazinium salts", 《TETRAHEDRON LETTERS 》 * |
任晓杰 等: "新型荧光染料的设计、合成、性能研究及生物应用", 《第十届全国化学生物学学术会议》 * |
方倩: "苯并吩恶嗪类(O、S、Se)水溶性光敏剂的合成与光学性能研究", 《中国学位论文全文数据库》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109513004A (en) * | 2018-11-26 | 2019-03-26 | 中南大学湘雅三医院 | A kind of photosensitizer and preparation method thereof for photodynamic therapy |
CN109513004B (en) * | 2018-11-26 | 2021-07-23 | 中南大学湘雅三医院 | A kind of photosensitizer for photodynamic therapy and preparation method thereof |
WO2023092708A1 (en) * | 2021-11-25 | 2023-06-01 | 深圳先进技术研究院 | Cell-penetrating riboflavin complex and application thereof in preparation of photodynamic therapy drug |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhuang et al. | Type I photosensitizers based on phosphindole oxide for photodynamic therapy: apoptosis and autophagy induced by endoplasmic reticulum stress | |
CA2457856C (en) | Sulphonated meso-tetraphenyl chlorins and their use as therapeutic agents | |
Lei et al. | Antibacterial photodynamic peptides for staphylococcal skin infection | |
Huang et al. | Investigation of copper-cysteamine nanoparticles as a new photosensitizer for anti-hepatocellular carcinoma | |
CN104940950B (en) | A kind of cancer target polypeptide sensitising agent key compound | |
Zhu et al. | An NIR triphenylamine grafted BODIPY derivative with high photothermal conversion efficiency and singlet oxygen generation for imaging guided phototherapy | |
AU2002212867B2 (en) | Photosensitizer and method for production thereof | |
CN104800855A (en) | Tumor-targeting fusion protein drug vector for optical imaging and photodynamic therapy | |
CN107936091A (en) | One kind targeting cell-penetrating peptide photosensitizer and its preparation method and application | |
WO2019090802A1 (en) | Diglycosylated benzophenoxazine photosensitizer and preparation method and use thereof | |
Liu et al. | Mitochondria‐Targeted Water‐Soluble Organic Nanoparticles of Chlorin Derivatives for Biocompatible Photodynamic Therapy | |
CN115531344B (en) | Multifunctional calcium-manganese nano modulator for resisting tumor and enhancing immunotherapy by remodelling tumor microenvironment | |
CN103861104A (en) | Phycocyanin-phthalocyanine compound and preparation method and application thereof | |
CN108164570A (en) | A kind of photosensitizer containing selenium and its preparation method and application | |
CN113384698B (en) | Self-assembled nano-medicament for synergetic chemotherapy/acousto-photodynamic therapy and application thereof | |
CN108129475A (en) | A kind of biology photosensitizer and its preparation method and application | |
CN107903258A (en) | A kind of fat-soluble photosensitizer and its preparation method and application | |
CN112402608B (en) | Application of 5-alkoxyindole-3-vinylquinoline salts as targeted transferable photosensitizers | |
WO2024040728A1 (en) | Platinum-based drug carbon nanodot, and method for preparing same and carbon nanodot protein compound and use thereof | |
Zhang et al. | In vitro and in vivo antitumor activity of a novel chlorin derivative for photodynamic therapy | |
AU2002313562C1 (en) | Compound | |
CN116602925A (en) | Nanometer medicine for treating tumor by light triggering active oxygen enhancement combination and preparation method thereof | |
CN118978525A (en) | A photosensitizer based on photoactivated labeling of RNA using phenothiazine and its preparation method and application | |
CN118344406A (en) | Lysosome-targeted ruthenium complex and preparation and application thereof | |
WO2012006780A1 (en) | Phthalocyanine-serum albumin complex, method for preparation and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180420 |